|
Integrated Pharmaceuticals Files with
SEC and Standard & Poor's
FITCHBURG, Mass., Oct. 5 /PRNewswire-FirstCall/
-- Integrated Pharmaceuticals, Inc (INTP.PK) announced today
that it has filed a Form 10SB registration statement with
the United States Securities Exchange Commission, which is
now available on the SEC's EDGAR website; it has sent an information
statement to market makers intended to comply with SEC rule
15c2-11; and its corporate information will be made available
via Standard & Poor's Market Access Program. The S&P program
is an information distribution service that enables subscribing
publicly traded companies to have their company information
disseminated to users of Standard & Poor's Advisor Insight.
If the Form 10SB becomes effective, IntePharm
will then be an SEC-reporting company under the Securities
Exchange Act of 1934. As such, it will be required to file
quarterly financial statements, annual reports, and numerous
other filings with the SEC.
Standard & Poor's Advisor Insight is an Internet-based
research engine used by more than 100,000 investment advisors.
A public version of the site is available at http://www.advisorinsight.com.
In addition, information about IntePharm will be available
via S&P's Stock Guide database, which is distributed electronically
to virtually all major quote vendors; and in the Daily News
section of Standard Corporation Records, a recognized securities
manual for secondary trading in approximately 37 states under
the Blue Sky Laws.
About the Company
IntePharm is a development stage biotechnology
company that seeks to discover and develop more efficient
and cost-effective ways to manufacture specialty pharmaceutical
products. IntePharm uses a comprehensive technology platform
that combines the application of metabolic engineering, cellular
genetics, advanced bioprocess engineering, and computer simulation
science for the development of efficient manufacturing programs
for recombinant proteins, small molecule therapeutics and
biopharmaceuticals for the treatment of degenerative, immunodeficiency,
and infectious diseases. The company has several market-ready
products in the pipeline that it plans to manufacture in the
near future.
For further information please contact Dr.
Chinmay Chatterjee, Integrated Pharmaceuticals, Inc. at (978)
696-0020, or visit http://www.intepharm.com.
Forward-Looking Statements
Certain statements contained in this press
release that are not historical facts constitute "Forward-Looking
Statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements, in general,
predict, indicate or imply future results, performance or
achievements and generally use words so indicative. Such forward-looking
statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results or performance
of the Company and its business to be materially different
from that expressed or implied by such forward-looking statements.
Included in those factors are the following: general economic
and business conditions; sales and revenues mix; pricing levels;
changes in sales and revenues to, or the identity of significant
customers; changes in technology; industry capacity and production
rates; ability of outside third parties to comply with their
commitments; competition; capacity constraints; availability
of raw materials and adequate labor; availability of appropriate
professional expertise; and availability of liquidity sufficient
to meet the Company's needs. Forward-looking statements by
their very nature are uncertain. There can be no guarantee
that any forward-looking statement will be fulfilled. The
Company assumes no obligation to update forward-looking statements
to reflect actual results or changes in or additions to the
factors affecting such forward-looking statements.
SOURCE Integrated Pharmaceuticals, Inc.
Web Site: http://www.intepharm.com
Copyright © 1996-2004 PR Newswire Association
LLC. All Rights Reserved. A United Business Media company.
|
